When Cancer Treatment Triggers Type 1 Diabetes: What Patients Should Know

Immune checkpoint inhibitors are an important class of cancer drugs that help the immune system fight tumors. But like all medications, they come with potential side effects. One of the most serious—though rare—is the development of Type 1 diabetes.

This condition, called ICI-induced Type 1 diabetes mellitus (ICI-T1DM), occurs when the immune system begins attacking insulin-producing cells in the pancreas, similar to naturally occurring Type 1 diabetes. A new systematic review and meta-analysis examined 10 studies involving nearly 66,000 cancer patients to better understand how often this happens and who is most at risk.

Among patients treated with immune checkpoint inhibitors, ICI-T1DM developed in approximately 0.58% of cases—roughly 1 in 170 patients. While this is a small percentage, the absolute number of affected patients is meaningful given how widely these drugs are used in cancer care.

The review found that about 37% of patients who developed ICI-T1DM presented with diabetic ketoacidosis (DKA), a dangerous condition where the body produces too many ketones and the blood becomes acidic. This serious complication underscores why early detection matters.

The analysis revealed an important distinction: patients receiving combination ICI therapy—two checkpoint inhibitors at the same time—had significantly higher risk of developing Type 1 diabetes compared to those on single-drug treatment.

Interestingly, having pre-existing diabetes before starting ICI therapy was not associated with increased risk of developing ICI-T1DM, suggesting the mechanism behind this side effect is distinct from typical diabetes risk factors.

The findings support regular glucose monitoring for all patients undergoing ICI therapy, particularly those receiving combination regimens. Early detection can help prevent serious complications like diabetic ketoacidosis.

If you are receiving immune checkpoint inhibitors for cancer treatment, discuss blood sugar monitoring with your care team. Symptoms like increased thirst, frequent urination, or unusual fatigue warrant prompt medical attention, as they can signal diabetes development or other metabolic changes.

Source: Diabetes research and clinical practice. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.